Amylyx Pharmaceuticals Appoints Jeffrey Trigilio Chief Financial Officer

New Chief Financial Officer Brings Expertise in Business Development and Pipeline Diversification Planning

CAMBRIDGE, Mass.–(BUSINESS WIRE)–
Amylyx Pharmaceuticals, Inc., a pharmaceutical company focused on developing new treatments for amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases, today announced the appointment of Jeffrey Trigilio as the company’s first Chief Financial Officer. In this new role, Jeff will lead the company’s financial strategy and business growth and development.

Jeff is as an accomplished financial professional with biotechnology experience from operational as well as investment banking and capital markets roles. Prior to joining Amylyx, Jeff most recently served as Vice President of Finance at BlueRock Therapeutics, an engineered cell therapy company focused on neurology, cardiology and immunology with a lead program in Parkinson’s disease. While there, he oversaw the finance department and served on BlueRock’s Leadership Team. Jeff helped develop BlueRock’s capital formation plan and enhanced key business processes and systems to facilitate rapid organizational growth.

Previously, Jeff held roles of increasing responsibility at Alexion Pharmaceuticals, a global biotechnology company focused on rare diseases, in corporate strategy and finance, most recently serving as Executive Director, Strategic Decision Analysis. At Alexion, he worked closely with executive leadership on long range planning, mergers and acquisitions, manufacturing, pricing and reimbursement and tax planning throughout a significant growth period during which the company expanded into multiple products and therapeutic areas.

“We are thrilled to welcome Jeff to the Amylyx team as we move toward commercialization,” said Justin Klee, Co-Founder and President of Amylyx. Joshua Cohen, Co-Founder and CEO at Amylyx added, “Jeff shares our vision and mission and with his experience will be instrumental as we strive to bring therapeutic options forward for patients.”

Jeff added, “I am very excited to join Amylyx at a pivotal moment following its recent clinical success in ALS and in anticipation of the completion of its ongoing Alzheimer’s trial. I look forward to helping Amylyx with the strategic and financial planning that will enable it to develop therapies globally in ALS, Alzheimer’s, and other neurodegenerative conditions where patients are waiting for new options.”

Jeff also has experience in investment banking covering healthcare and biopharmaceutical companies at both Credit Suisse and RBC Capital Markets. He holds a B.S. from Cornell University and an MBA from Columbia Business School.

About Amylyx Pharmaceuticals

Amylyx Pharmaceuticals, Inc. is a pharmaceutical company developing a novel therapeutic for Amyotrophic Lateral Sclerosis (ALS), Alzheimer’s disease and other neurodegenerative diseases. For more information, visit www.amylyx.com and follow us on LinkedIn and Twitter.


Merissa Muller

Account Executive

Finn Partners

(212) 715-1699

Merissa.muller@finnpartners.com

Source: Amylyx Pharmaceuticals, Inc.